Freak

[Freak @freakishhuman]

Thinking about this fucking thing again

[Freak @freakishhuman]

@jorslan North is North retard

[Quokka 🏳️‍🌈 @Q2Quokka]

The insane homeless guy on the train

[marrowing @marrowing]

Tom Holland’s non alcoholic beer brand. fuck off (my face softens) ah, what the hell. pass me a Bero brother

[Freak @freakishhuman]

@jorslan We are not the same

[gabe, allegedly @untiloasis]

i’ll never forget walking out of the theater going “wow that fixed EVERY problem i had with The Force Awakens i’m excited about star wars again” & then everyone lost their fucking minds

[xwetoo😱 @xWetoo_]

Holy Mog gościu

[mollynew @FearInherent]

Fascism but leftistly

[TaxedBrass @FakeTaxedBrass]

Evil Hassan Piker

[Sultan Boushahri @SBoushahri]

@pelagiusreborn Err, the reason people bring up Claviculars looks is because that is his brand/persona (Looksmaxxing). When that’s the image you constantly project and center your identity around, it becomes the lens through which people evaluate you.

[🦋charlotte @alayneofstone]

why is the actor lwk mad about it too like😭😭😭😭

[Acooless @acooless]

EU CS players queuing up and seeing 0 russians in their lobbies

[Freak @freakishhuman]

Do you remember when you joined X? I do! #MyXAnniversary

[Fredda @PunishedFredda]

I kinda wish this series was more trying to do Heat without the consequences and less Vermintide but the Skaven are the NYPD

[Seth Dirks @SirDustyDirks]

Valve: 350 employees
Epic Games: 4,000 employees

Valve: $17B annual revenue
Epic Games: $5-6B

Valve charges devs 30% of their revenue for simply listing their game.

Epic Games charges devs 0% revenue share on the first $1,000,000

Valve is one of the greediest companies in gaming. You cannot be pro valve and be pro developer at the same time.

[Avi Bitterman, MD @AviBittMD]

This is basically on the level of Hasan Piker endorsing Ivermectin for COVID during the early slop trial publication days.

The claimed "working" treatment for Alzheimer's has an non-replicated and a biologically implausible effect size result that should call its trial into question.

Specifically, the effect size in the ATHENEA trial (NeuroEPO plus) appears implausibly large when benchmarked against decades of Alzheimer's disease clinical trial data, particularly on the primary outcome: change in ADAS-Cog11 score at 48 weeks.

Median ADAS-Cog11 change: -3.0 to -4.0 points (improvement) in the two active doses.

Placebo: +4.0 points (worsening).

Net treatment differences: 7.0 to 8.0 points

This equates to treatment groups showing cognitive improvement while placebo worsened substantially, yielding an absolute benefit of ~7-8 points over 48 weeks.

Not only is this far greater than the largest realistic effects in approved/symptomatic therapies (Donepezil, rivastigmine, galantamine: Peak benefits of 2–4 points vs. placebo, often at 6–12 months, then fading), it further shows an even more implausible reversal of disease.

AD is relentlessly progressive; no neuroprotective agent (including EPO variants in other trials) has reversed cognitive scores. At best, one can hope for slowing or halting the disease.

Improvement reported in this trial suggests reversal of deficits, and all in the face of discordant data. Hippocampal volumetry was neutral in the RCT: identical atrophy rates across active and placebo arms.

Percentage change: ≈ −3.40% (0.5 mg dose), −3.26% (1.0 mg), −3.32% (placebo); p ≈ 0.98 (neutral across arms).

This indicates no slowing of hippocampal atrophy despite the large cognitive benefits claimed.

Cognitive reversal without any slowing of structural neurodegeneration is biologically discordant. AD cognition tracks closely with hippocampal loss. The authors speculated about “functional/synaptic” benefits to try and explain this, but this remains speculative and would require extraordinary evidence (synaptic density imaging, which wasn’t done).

In other words: The brain continues to die, but the paper is reporting clinical reversal of disease. That is a huge red flag of discordance and should call the trial results into serious question.

The manufacturer of this drug (Center of Molecular Immunology) designed, funded, analyzed, and authored both this trial and the follow-up study with even more far-reaching, less plausible results (this alone does not invalidate the results, but it should be noted in light of the implausible results).

To date, this has never been replicated, and every published human clinical trial result (efficacy, safety, follow-up) on NeuroEPO/NeuralCIM in Alzheimer's is from Cuban research teams, sites, and sponsors (primarily CIM).

If this is truly the Ivermectin-that-actually-works-miracle-story for Alzheimer's...great, I look forward to seeing the replication outside of Cuba.

Until then, you should be skeptical, and you should definitely stop taking Hasan Piker seriously on medical treatments.

[Oil Baron 🇺🇸 🛢️ 🦅 @OilBar0n]

Founded by Alexander Hamilton btw

[Keifer @DannyVegito]

drop the “media.” just “illiterate.” it’s cleaner.

[Freak @freakishhuman]

@yuanyi_z &Korea &Iraq &GW &Afganistan, even have basically a US mil owned and operated spy base on our soil. I understand Strong Mil prtnrship essential for NS, but in RT America has tarrifed & removed elected PMs. time to find new Sec partnerships man. Goes beyond current admin. Fuck AMR

[Eli 🍚 @EliLikesRice]

Even hotter take but I think reloading should just put the mag back in reserve, like the reload system in Squad where you have a certain amount of magazines and if you reload, the mag with less bullets stays that way